Genelux Corporation Board of Directors

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Mr. Thomas Zindrick J.D.

Mr. Thomas Zindrick J.D.

Chairman, CEO & President

Mr. Sean Ryder J.D.

Mr. Sean Ryder J.D.

General Counsel & Corporate Secretary

Dr. Joseph Cappello Ph.D.

Dr. Joseph Cappello Ph.D.

Chief Technical Officer

Ms. Lourie S. Zak

Ms. Lourie S. Zak

Chief Financial Officer

Mr. Ralph Smalling B.Sc.

Mr. Ralph Smalling B.Sc.

VP & Head of Regulatory Affairs

Dr. Yong Yu Ph.D.

Dr. Yong Yu Ph.D.

Senior Vice President of Clinical Development

Comments